Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

BACKGROUND: Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse events in patients with metastatic renal cell carcinoma. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I., Cohen, Darrel P., Lu, Dongrui R., Chen, Isan, Hariharan, Subramanian, Gore, Martin E., Figlin, Robert A., Baum, Michael S., Motzer, Robert J.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086879/
https://www.ncbi.nlm.nih.gov/pubmed/21527770
http://dx.doi.org/10.1093/jnci/djr128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086879/
https://www.ncbi.nlm.nih.gov/pubmed/21527770
http://dx.doi.org/10.1093/jnci/djr128

Ejemplares similares